SEC 指控创始人兼前副总裁 Cassava Sciences $40M 对阿尔茨海默病治疗试验的误导性陈述，未认罪。 SEC charges Cassava Sciences, founder, and ex-VP $40M for misleading statements on Alzheimer's treatment trial, no admission of guilt.
证交会指控Cassava科学公司和两名前执行官对老年痴呆症治疗临床试验作出误导性陈述。 The SEC has charged Cassava Sciences and two former executives for making misleading statements regarding a clinical trial for an Alzheimer's treatment. 该公司与创始人Remi Barbier和前任总裁Lindsay Burns博士一起,将支付4 000多万美元,在不承认不法行为的情况下解决指控。 The company, along with founder Remi Barbier and ex-vice president Dr. Lindsay Burns, will pay over $40 million to settle the charges without admitting wrongdoing. 该公司与调查合作,并实施了纠正措施,使其能够把重点放在正在进行的临床试验上。 The company has cooperated with the investigation and implemented corrective measures, allowing it to focus on ongoing clinical trials.